anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pulmonary embolism (PE) is commonly treated primarily with pharmacological therapy, while advanced reperfusion therapies (transcatheter or surgical) are considered only in cases of contraindications or failure of standard therapies. Treatment algorithms vary depending on the patient's risk, with patients at intermediate or high risk potentially requiring evaluation for such advanced reperfusion therapies. Critical scenarios, such as contraindications to systemic thrombolysis or failure of pharmacological protocols, necessitate the activation of a multidisciplinary pulmonary embolism response team (PERT) and prompt therapeutic escalation. Integrated in-hospital pathways and the extension of PERT at the provincial/regional level are recommended to improve access to advanced therapies and promote uniform management of PE. Larger randomized clinical trials are needed to assess the efficacy of transcatheter therapies compared to current standards. In conclusion, a multidisciplinary and standardized approach, supported by evidence-based guidelines, is essential to optimize PE management and improve clinical outcomes. The Italian Society of Interventional Cardiology (SICI-GISE) aims to promote such standardization nationally with this expert position paper, ensuring appropriateness and equity of care for patients, as well as fostering further scientific research and education.
Gut dysbiosis is linked to metabolic and neurodegenerative diseases and comprises a plausible link between high-fat diet (HFD) and brain dysfunction. Here we show that gut microbiota modulation by either antibiotic treatment for 5 weeks or a brief 3-day fecal microbiota transplantation (FMT) regimen from low-fat (control) diet-fed mice decreased weight gain, adipose tissue hypertrophy, and glucose intolerance induced by HFD in C57BL/6 male mice. Notably, gut microbiota modulation by FMT completely reversed impaired recognition memory induced by HFD, whereas modulation by antibiotics had less pronounced effect. Improvement in recognition memory by FMT was accompanied by decreased HFD-induced astrogliosis in the hippocampal cornu ammonis region. Gut microbiome composition analysis indicated that HFD diminished microbiota diversity compared to control diet, whereas FMT partially restored the phyla diversity. Our findings reinforce the role of the gut microbiota on HFD-induced cognitive impairment and suggest that modulating the gut microbiota may be an effective strategy to prevent metabolic and cognitive dysfunction associated with unfavorable dietary patterns.
Reference drug "BR1016D" 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug "BR1016C" 1 tablet is administered once in fasted state.
PROBLEM TO BE SOLVED: To obtain the subject composition comprising an organopolysiloxane, an organohydrogenpolysiloxane, a silicone-soluble platinum compound, methylphenylpolysiloxane, an inorganic filler and a surfactant in order to carry out the taking of an impression of a mucous membrane of an oral cavity with a good accuracy when preparing and regulating a denture. SOLUTION: This composition comprises (A) 100 pts.wt. of an organopolysiloxane having at least 2 aliphatic unsaturated hydrocarbons in one molecule and 500-1,500 cSt viscosity at 25 deg.C, (B) 0.1-20 pts.wt. of an organohydrogenpolysiloxane having at least 3 hydrogen atoms directly bound to silicon atom in one molecule, (C) a silicone-soluble platinum compound in an amount of 10-500 ppm based on the total amount of the components A and B, (D) 1-20 pts.wt. of a linear methylphenylpolysiloxane having 30-10,000 cSt viscosity at 25 deg.C, (E) 10-200 pts.wt. of an inorganic filler and (F) 0.5-5 pts.wt. of a nonionic surfactant.
Copper is primarily excreted in the bile. Excretion is decreased in patients with cholestasis and/or cirrhosis. Manganese is presumed to be excreted in bile [see Clinical Pharmacology (12.3)]. Hepatic accumulation of copper and manganese has been reported with long-term administration of parenteral nutrition at dosages higher than recommended [see Warnings and Precautions (5.4)].

For patients with cholestasis or cirrhosis, monitor hepatic and biliary function during long-term administration of Multrys. 

If a patient develops signs or symptoms of hepatobiliary disease during use of Multrys, obtain serum concentrations of copper and ceruloplasmin as well as manganese whole blood concentrations; consider using individual trace element products in these patients.
Clostridioides difficile, a cause of healthcare-associated infections, poses a significant global health threat. This multi-institutional retrospective study focuses on epidemic dynamics, emphasizing minor and toxin-negative clinical isolates through high-resolution genotyping. The genotype of the C. difficile clinical isolates during 2005 to 2022 was gathered from 14 hospitals across Japan (N = 982). The total number of unique genotypes was 294. Some genotypes were identified in every hospital (cross-regional genotypes), while others were unique to a specific hospital or those in close geographic proximity (region-specific genotypes). Notably, a hospital located in a sparsely populated prefecture exhibited the highest prevalence of region-specific genotypes. The isolation rate of cross-regional genotypes positively correlated with the human mobility flow. A 6-month interval analysis at a university hospital from 2019 to 2021 revealed a temporal transition of the genotype dominance. The frequent isolation of identical genotypes over a brief timeframe did not always align with the current criteria for defining nosocomial outbreaks. This study highlights the presence of diverse indigenous C. difficile strains in regional environments. The cross-regional strains may have a higher competency to spread in the human community. The longitudinal analysis underscores the need for further investigation into potential nosocomial spread.
ALZ-801 265 mg BID tablet orally. Subjects will take one 265 mg tablet of ALZ-801 in the evening during the first 4 weeks of the study; thereafter, they will take one 265 mg tablet BID.
INTRODUCTION: Obesity is a chronic disease that increases cardiovascular and metabolic morbidity and mortality, decreases quality of life, and increases health care costs. While the role of lifestyle behavioral factors in the development of obesity is well established, the role of traumatic life events, including violence, is unclear. The purpose of this study was to describe situations of traumatic life events reported by patients undergoing a bariatric surgery program, with a particular focus on sexual violence and its clinical correlates.
METHODS: In this cross-sectional study, patients with grade II or III obesity, admitted to our digestive surgery department for bariatric surgery from August 01, 2019, to December 31, 2020, underwent a structured interview by a trained psychologist to describe the history of traumatic life events self-reported by the patients. The primary endpoint was the presence of a history of sexual violence (SV). Multivariate logistic regressions were applied to identify independent risk factors for SV.
RESULTS: Of the 408 patients interviewed, 87.1% reported at least one traumatic life event and 33.1% reported having had an SV in the past. Female gender (aOR = 7.44, 95% confidence interval: 3.85-15.73; p < 0.001) and higher body mass index (1.05, 1.02-1.08; p = 0.002) were associated with an increased risk of SV. Male gender was associated with a higher risk of difficulties including sports cessation, depression, and work-related distress.
CONCLUSION: In the context of obesity, psychosocial trauma is characterized by a high frequency and several gender specificities that must be taken into account in the management of these patients.
Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It received FDA approval for the treatment of neovascular age-related macular degeneration (nAMD) in October 2019 followed by EMA approval in February 2020. Brolucizumab received marketing approval based on the two pivotal phase 3 clinical trials - HAWK and HARRIER - with a q8/q12 week dosing regimen. Potential benefits of brolucizumab are assumed to be related to its low molecular weight with subsequent better tissue penetration as well as higher molar concentration. This could improve the treatment durability and lower the burden for patients and caregivers when dealing with repetitive intravitreal treatments and monitoring visits over a long period of time in a chronic disease. However, safety signals have been reported in both RCTs and post-marketing reports, which included the occurrence of intraocular inflammation (IOI) and retinal vasculitis with or without occlusion.

In this study we want to share our early results and experience with Bolucizumab in UZ Leuven. By retrospective analysis of a cohort of 17 patients treated with Brolucizumab, we evaluate the efficacy of the drug as well as the occurrence of adverse-events, especially intra-ocular inflammation and vasculitis.
The effectiveness of levetiracetam as adjunctive therapy in patients 6 years of age and older with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic (PGTC) seizures was established in one multicenter, randomized, double-blind, placebo-controlled study (Study 7), conducted at 50 sites in 8 countries. Eligible patients on a stable dose of 1 or 2 antiepileptic drugs (AEDs) experiencing at least 3 PGTC seizures during the 8-week combined baseline period (at least one PGTC seizure during the 4 weeks prior to the prospective baseline period and at least one PGTC seizure during the 4-week prospective baseline period) were randomized to either levetiracetam or placebo. The 8-week combined baseline period is referred to as "baseline" in the remainder of this section. Patients were titrated over 4 weeks to a target dose of 3000 mg/day for adults or a pediatric target dose of 60 mg/kg/day and treated at a stable dose of 3000 mg/day (or 60 mg/kg/day for children) over 20 weeks (evaluation period). Study drug was given in 2 equally divided doses per day. The primary measure of effectiveness was the percent reduction from baseline in weekly PGTC seizure frequency for levetiracetam and placebo treatment groups over the treatment period (titration + evaluation periods). The population included 164 patients (Levetiracetam N=80, placebo N=84) with idiopathic generalized epilepsy (predominately juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening) experiencing primary generalized tonic-clonic seizures. Each of these syndromes of idiopathic generalized epilepsy was well represented in this patient population.

There was a statistically significant decrease from baseline in PGTC frequency in the levetiracetam -treated patients compared to the placebo-treated patients.

The percentage of patients (y-axis) who achieved ≥50% reduction in weekly seizure rates from baseline in PGTC seizure frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in Figure 6.

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7
PURPOSE: To obtain a pharmaceutical composition containing dermatan sulfate or the combination of the dermatan with heparin as an active ingredient and useful for preventing and treating the aging of brains and the insufficient function states of central nervous systems. CONSTITUTION: This pharmaceutical composition contains natural dermatan sulfate having an average mol.wt. of 20,000-40,000 dalton or low mol.wt. dermatan sulfate having an average mol.wt. of 3,000-20,000 dalton or the combination of the dermatan sulfate with 0.5-10wt.% of heparin as an active ingredient. The composition is useful for treating central nervous system hypofunctions related to the biochemical modulation of glycosaminoglycan sulfate due to toxic dependency caused by the excessive use of a drug and for treating the ageing of brains in the forms of childish and senile dementias which are the syndromes of insufficient metabolisms.
Double pulse TMS method used to investigate the influence of the pIPS on M1 excitability. We set the ST intensity to evoke a 1mV MEP in the first dorsal interosseous muscle. The SC is applied at 90% of the MT on the pIPS. Our study involves two phases: Resting Phase: 10 single ST and 10 SC+ST doublets with a 4ms interstimulus interval. ST intensity is set to evoke a 1mV MEP, and SC is at 90% of the motor threshold. Movement Phase: Subjects perform a specific hand movement in response to colored light signals (green or red) projected on a screen. A brief but non-painful stimulus may coincide with the red signal to induce a fear response. A test stimulus (ST) or SC+ST doublet is delivered with a 500ms delay after each signal, allowing us to explore corticocortical influences during motor programming. 40 stimulations in total are delivered during this phase. Note that only 40 trials will be performed, and there will be no painful stimuli.
Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
<P>PROBLEM TO BE SOLVED: To save hardware resources in a user side and reduce a service cost.  <P>SOLUTION: A user's terminal 21 transmits the contents of a prescription received by an operation console 2E to a host computer 10 via a network 1. The host computer 10 creates scan control data for controlling the operation of a scanner body 2B according to the contents of the prescription and transmits them to the user's terminal 21. The user's terminal 21 controls the operation of the scanner body 2B based on the scan control data, collects raw data, and transmits them to the host computer 10. The host computer 10 processes the raw data to produce a medical image, and transmits it to the user's terminal 21. The user's terminal 21 displays the medical image on the screen. This constitution can save the equipment cost with the scanner body in the user side and quickly perform the maintenance of the software at a low cost.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:To provide a gel ointment containing indomethacin, glycerol, a monohydric or dihydric alcohol, a gelling agent and water, and having high solubility and stability. CONSTITUTION:The objective gel ointment contains 0.05-5wt% of indomethacin, 1-30wt% of glycerol, 30-70wt% of a monohydric or dihydric alchol, 0.5-5wt% of a gelling agent (e.g. carboxyvinyl polymer, methyl cellulose, etc.) and the remaining part of water. Indomethacin is used widely as a non-steroidal anti- inflammatory and analgesic agent, however, it has poor solubility in water, and its stability is sensitive to the kind of the substrate. The solubility of indomethacin is improved in the present gel ointment, and the ointment keeps firm gel property, prevents the crystal precipitation and discoloration of indomethacin for a long period, and exhibits high stability. Accordingly, the drug action of indomethacin can be developed stably.
PURPOSE:To obtain a long-acting preparation remaining in the stomach over a long period after oral administration, capable of releasing the drug in the stomach over a long period and composed of multiple units by applying a drug to the surface of a hollow granule formed by the volume decrease of a highly water-absorbing polymer. CONSTITUTION:A hydrogel having high gel strength is produced by absorbing water to a highly water-absorbing polymer (e.g. a polyacrylic acid salt). The hydrogel is coated with a coating film made of an assistant for drug preparation and dried to obtain a granule having a cavity (hollow granule) by the volume decrease of the hydrogel. The hollow granule is coated with a polymer scarcely soluble and/or insoluble in gastric juice (e.g. ethyl cellulose) to obtain granules floating in the stomach. The objective medicine can be prepared by coating the granule with a polymer coating agent compounded with a drug component. The polymer coating agent compounded with a drug component is a mixture of a polymer soluble in the stomach (e.g. hydroxypropyl cellulose), a polymer scarcely soluble and/or insoluble in gastric juice and a drug component (e.g. arotinolol hydrochloride).
<P>PROBLEM TO BE SOLVED: To provide an assay for identifying beta-secretase inhibitor, and to provide a screening method.  <P>SOLUTION: This assay for identifying inhibitors of beta-secretases comprises the steps of immobilizing a beta-secretase protein on a solid support, contacting it with a test compound in the presence of a tagged beta-secretase inhibitor, and comparing the extent of binding of the tagged beta-secretase inhibitor in the presence and in the absence of the test compound in order to evaluate if the test compound is an inhibitor of beta-secretases. A method of screening for inhibitors of beta-secretases. Novel beta-secretase inhibitors and their use as tagged beta-secretase inhibitors for identification of inhibitors of beta- secretase. A kit for identifying beta-secretase inhibitors. Novel beta-secretase inhibitors for use in the treatment of Alzheimer's disease and other cerebrovascular amyloidosis.  <P>COPYRIGHT: (C)2003,JPO
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to radiation therapy, and aims at prevention and treatment of cystitis in pelvic radiation therapy. For the treatment and prevention of radiation cystitis Colegel-Gial and Colegel-ADL are installed during irradiation. Additionally, installation of Coletex-D hydrogel napkins and Colegel-Gial in 10–60 ml every 7–10 days and 1 day before the irradiation course are performed. During the irradiation course, under the control of the urine values, Colegel-Gial installations are performed, and 45–60 minutes later, Coletex-D hydrogel napkins 10 ml 2–3 times a week until the leucocytes in urine 20 are recorded in the visual field. If observing the achievement or exceeding of this value, the Colegel-Gial urine catheter is instilled and after 45-60 minutes, Coletex-ADL hydrogel napkins are taken 10 ml before the irradiation course. After the irradiation course, the urine parameters are controlled by the Coletex-beta hydrogel tissue 20 ml 1–2 times a week before the urine leucocyte count is determined to be no more than 6 in the female vision field and not more than 4 in the male vision field.EFFECT: use of the invention enables patient's comfort enhancement by reducing the soreness of procedures and the risk of urogenital tract injuries, improved quality of life of the patients both at the stage of radiotherapy and post-ray period, as well as higher clinical effectiveness by reducing the probability and frequency of interruptions in treatment and, consequently, reducing the risk of post-radial cystitis and reducing the recovery period of the patients and the time of disability.1 cl, 4 ex
Hemophagocytic lymphohistiocytosis (HLH) is a severe and frequently underdiagnosed disorder of systemic immune dysregulation resulting in hypercytokinemia and histologically evident hemophagocytosis, We report a case of a 34-year-old man who presented with breathlessness, generalized weakness, and fever of unknown origin with pancytopenia. Clinically the patient was admitted for febrile illness, and treated symptomatically but his general condition worsened leading to death within 21 hours of admission. A complete autopsy was performed. The deceased had a significant past history of repeated episodes of fever, weight loss, and axillary lymphadenopathy over a period of 8 months with multiple hospital admissions. He was also diagnosed with enteric fever (Widal test and Typhi IgM positive) at the start of these episodes. Hemogram during this period revealed persistent pancytopenia. Serum ferritin, serum triglycerides, and liver function tests were consistently deranged. Investigations for the etiology of fever and blood cultures were negative while the bone marrow aspirate revealed a normocellular marrow. CT abdomen-pelvis showed mild hepatomegaly with enlarged retroperitoneal lymph nodes. Infective endocarditis, lymphoma, and bronchopneumonia were being considered the clinical diagnoses. The significant autopsy findings were hepatosplenomegaly with retroperitoneal lymphadenopathy and multiple gastric ulcers. On microscopy, the liver, spleen, bone marrow, and lymph nodes showed characteristic hemophagocytosis. Post-mortem histopathological examination clinched the diagnosis of HLH and fulfilled six out of eight diagnostic criteria of the HLH-2004 protocol. We discuss the clinical course and diagnosis of this unique case and strive to create awareness about secondary HLH induced by common diseases, such as enteric fever.
Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily \[morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00\], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drugs cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CAYSTON was evaluated in 344 patients from two placebo-controlled trials and one open-label follow-on trial. In controlled trials, 146 patients with CF received 75 mg CAYSTON 3 times a day for 28 days.

Table 1 displays adverse reactions reported in more than 5% of patients treated with CAYSTON 3 times a day in placebo-controlled trials. The listed adverse reactions occurred more frequently in CAYSTON-treated patients than in placebo-treated patients.

Adverse reactions that occurred in less than 5% of patients treated with CAYSTON were bronchospasm (3%) [see Warnings and Precautions (5.2)] and rash (2%).
Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).